## LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449

(Use several sheets if necessary)

Sheet 1 of 5

	ATTY. DOCKET NO.:	APPLICATION NO.:			
	88066-7900	10/798,111			
	APPLICANT:				
CARRARA et al.					
	FILING DATE:	GROUP:			
	March 10, 2004	1614			

## ILS. PATENT DOCUMENTS

			U.S. PAT	ENT DOCUMENTS		-	
*EXAMINER INITIAL	CITE NO.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	<b>A</b> 1	2001/0031787	10/2001	Hsu et al.	514	534	
	A2	2003/0147926	08/2003	Ebert et al.	424	400	
	A3	4,597,961	07/1986	Etscorn	424	448	
	A4	4,704,406	11/1987	Stanislaus et al.	514	570	
	A5	4,832,953	05/1989	Campbell et al.	424	448	
	A6	4,973,468	11/1990	Chiang et al.	424	449	
	A7	5,041,439	8/1991	Kasting et al.	514	227.2	
	A8	2004/0139990 A1	07/2004	Wachter et al.	134	25.4	
	A9	5,230,896	07/1993	Yeh et al.	424	443	
	A10	5,278,176	01/1994	Lin	514	343	
	A11	5,352,457	10/1994	Jenkins	424	448	
	A12	5,527,832	06/1996	Chi et al.	514	772.4	
	A13	5,603,947	02/1997	Wong et al.	424	448	
	A13	5,633,008	05/1997	Osborne et al.	424	448	
	A15	5,658,587	08/1997	Santus et al.	424	448	
	A16	5,662,890	09/1997	Punto et al.	424	59	
	A17	5,783,207	07/1998	Stanley et al.	424	440	
	A18	5,855,905	01/1999	Oettel et al.	424	426	
	A19	5,814,659	9/1998	Elden	514	452	
	A20	5,932,243	08/1999	Fricker et al.	424	450	
	A21	5,935,604	08/1999	Illum	424	501	
	A22	6,034,079	03/2000	Sandberg et al.	514	225.8	
	A23	6,165,497	12/2000	Osborne et al.	424	448	
	A24	6,166,044	12/2000	Sandborn et al.	514	343	
	A25	6,267,985 B1	07/2001	Chen et al.	424	451	
	A26	6,299,900 B1	10/2001	Reed et al.	424	449	
	A27	6,383,471 B1	05/2002	Chen et al.	424	45	
	A28	6,417,205 B1	07/2002	Cooke et al.	514	343	
	A29	6,426,078 B1	07/2002	Bauer et al.	424	401	
	A30	6,465,005 B1	10/2002	Biali et al.	424	449	
	A31	6,479,076 B2	11/2002	Blank	424	484	
	A32	6,586,000 B2	07/2003	Luo et al.	424	449	
	A33	6,596,740 B2	07/2003	Jones	514	343	
	A34	2003/0199426 A1	10/2003	Carrara et al.	514	2	
	A35	4,764,381	08/1988	Bodor et al.	424	449	

# LIST OF RE

A36 A37 A38 A39 A40 A41

<u>A</u>42

A43 A44 A45 A46 A47

A48 A49

A50 A51 A52 A53 A54 A55 A56

A57 A58 A59 A60 A61 A62 A63 A64 A65

A66

ATTY. DOCKET NO.: APPLICATION NO.:

						1	
REFERENCES CITED BY APPLICANT				88066-7900		10/798,111	
,	Form PTO-1449		APPLICANT:				
(	Use several sheets if neo		CARRARA et al.  FILING DATE: I GROUP:				
Sheet 2 of 5						GROUP:	
4,883,660 11/1989 Blackman				March 10, 2004		1614	
_	4,883,660	09/1990	Blackman	et al.	424	78	
	4,956,171 5,453,279		Chang Lee et al.		424	449	
_	5,719,197	09/1995 Lee et al		.1	514	772.6	*******
	5,785,991	07/1998	Burkoth et		424	448	······
	2003/0175329 A1	9/2003	Azarnoff et		424	449	
	2003/0222105 A1	12/2003	Lee et al.		222	382	
	5,164,190	11/1992	Patel et al.		424	448	
_	5,532,278	7/1996	Aberg et al		514	617	
_	5,601,839	2/1997	Quan et al.		424	448	
	5,677,346	10/1997	Aberg et al		51	617	
	5,736,577	4/1998	Aberg et al		514	617	
	5,834,010	11/1998	Quan et al.		424	448	
	5,900,250	5/1999	Lee et al.		424	448	
	6,123,961	9/2000	Aberg		424	468	
	6,124,355	9/2000	Guittard et	al.	514	534	***************************************
	6,432,446	8/2002	Aberg		424	468	
	6,545,046	4/2003	Sherratt et al		514	534	
	US 2001/0038855	11/2001	Desjardin e	t al.	424	468	
	US 2002/0147236	10/2002	Sanders et a	al.	514	540	
	US 2003/0095926	8/2002	Dugger, III		424	43	
	US 2003/0143278	7/2003	DiPiano et	al.	424	489	
_	2,990,332	6/1961	John W. Ke	eating	167	65	
_	3,143,465	8/1964	John W. Ke	eating	167	65	
	3,989,816	11/1976	Rajadhyaks	ha	424	60	
_	4,221,778	9/1980	Raghunatha	n	424	31	
	4,316,893	2/1982	Rajadhyaks	han	424	180	
_	4,405,616	9/1983	Rajadhyaks	ha	424	60	
_	4,557,934	12/1985	Cooper		424	128	
_	4,568,343	2/1986	Leeper et al	•	604	896	
	4,783,450	11/1988	Fawzi et al.		514	78	

#### ATTY. DOCKET NO.: APPLICATION NO.: LIST OF REFERENCES CITED BY APPLICANT 88066-7900 10/798,111 Form PTO-1449 APPLICANT: (*Use several sheets if necessary*) CARRARA et al. FILING DATE: GROUP: Sheet 3 of 5 March 10, 2004 1614 4,808,411 2/1989 Lu et al. A67 424 441 5/1992 Zierenberg et al. A68 5,112,842 514 367 A69 5,188,825 2/1993 Hes et al. 424 78.1 7/1992 A70 5,134,127 Stella et al. 514 058 A71 5,225,189 7/1993 Pena 424 70 12/1994 A72 5,376,645 Stella et al. 514 58 A73 5,843,482 12/1998 Rhodes et al. 424 653 12/1998 Sandborn et al. 514 A74 5,846,983 343 8/1999 Spanton et al. 29 A75 5,945,405 514 6,071,959 6/2000 Rhodes et al. A76 514 535 A77 10/2000 Stella 6,133,248 514 58 A78 6,238,689 B1 5/2001 Rhodes et al. 424 436 FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS YES NO 1 323 431 A2 07/2003 EP **B**1 07/2003 B2 1 323 430 A2 EP 1 325 752 A2 07/2003 EP **B3** 0 261 429 A1 03/1988 EP **B4 B**5 0 267 617 A1 05/1988 EP 0 271 983 A1 06/1988 EP **B6** 0 279 977 A2 08/1988 **B7** EP 0 367 431 A1 05/1990 EP **B8** B9 0 526 561 B1 02/1993 EP 10/1990 **PCT B10** WO 90/11064 A1 B11 WO 97/29735 A1 08/1997 **PCT** WO 98/17316 A1 04/1998 **PCT** B12 **PCT B13** WO 02/17967 A1 3/2002 WO 2004/037173 A2 5/2004 **PCT** B14 WO 95/18603 A1 07/1995 **PCT B15** WO 01/80796 A1 11/2001 **PCT B16 B17** WO 95/29678 A1 11/1995 **PCT B18** WO 97/38726 10/1997 **PCT**

### ATTY. DOCKET NO.: APPLICATION NO.: LIST OF REFERENCES CITED BY APPLICANT 88066-7900 10/798,111 Form PTO-1449 APPLICANT: (Use several sheets if necessary) CARRARA et al. FILING DATE: GROUP: Sheet 4 of 5 March 10, 2004 1614 NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Budavari et al., The Merk Index, 1996, Merck Research Laboratories, 12th Edition, pp. 253 and 269. C1 Kotivan et al., "Eudragits: Role as crystallization inhibitors in drugin-adhesive transdermal systems C2 of estradiol," European Journal of Pharmaceutics and Biopharmaceutics 52: 173180 (2001). Lipp, "Selection and use of crystallization inhibitors for matrixtype transdermal drug-delivery C3 systems containing sex steroids," J. Pharm. Pharmacol 50: 1343-1349 (1998). Moser et al., "Passive skin penetration enhancement and its quantification in vitro," European Journal C4 of Pharmaceutics and Biopharmaceutics 52: 103112 (2001). Mura et al., "Evaluation of transcutol as a clonazepam transdermal permeation enhancer from C5 hydrophilic gel formulations," European Journal of Pharmaceutical Sciences 9: 36-372 (2000). R. Panchagnula et al., "Development and evaluation of an intracutaneous depot formulation of corticosteroids using transcutolas a cosolvent: in-vitro, ex-vivo and in-vivo rat studies." J. Pharm. C6 Pharmacol. 1991, 43: 609-614. L. Pavliv et al., "Topical formulation development of a novel thymidylate synthase inhibitor for the C7 treatment of psoriasis," International Journal of Pharmaceutics 1994, 105: 227-233. W.A. Ritschel et al., "In vitro skin penetration of griseofulvin in rat and human skin from an C8 ointment dosage form," Arzneimittelforschung. 1988, 38(11): 16301632. W.A. Ritschel et al., "Use of sorption promotes to increase systemic absorption of coumarin from C9 transdermal drug delivery systems," Arzneimittelforschung. 1988, 38(12): 1774/777. W.A. Ritschel et al., "Development of an intracutaneous depot for drugs," Skin Pharmacol. 1991. C10 4:235-245. J. Rojas, "Optimization of binary and ternary solvent systems in the percutaneous absorption of C11 morphine base," S.T.P. Pharma Sciences 1991, 1(1): 7075. E. Touitou, "Enhanced permeation of the ophylline through the skin and its effect on fibroblast C12 proliferation," International Journal of Pharmaceutics 1991, 70: 159166. A. Watkinson, "Aspects of the transdermal delivery of prostaglandins," International Journal of C13 Pharmaceutics 1991, 74: 229-236. M. Yazdanian et al., "The effect of diethylene glycol monoethyl ether as a vehicle for topical delivery C14 of ivermectin," Veterinary Research Communications 1995, 19(4): 309319 English Abstract NLM2807923 XP-002337932, "Promoting Penetration Of Locally Applied C15

Substances By Urea".

## ATTY, DOCKET NO.: APPLICATION NO.: LIST OF REFERENCES CITED BY APPLICANT 88066-7900 10/798,111 Form PTO-1449 APPLICANT: (Use several sheets if necessary) CARRARA et al. FILING DATE: GROUP: Sheet 5 of 5 March 10, 2004 1614 NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) David W. Osborne et al., XP 002337808, "Skin Penetration Enhancers Cited in the Technical C16 Literature". A.C. Williams et al., XP 000645464, 'Urea Analogues In Propylene Glycol As Penetration C17 Enhancers In Human Skin", International Journal of Pharmaceutics, Vol. 36, pp.4350 (1989). Koichi Takahashi et al., "Effect of Vehicles on Diclofenac Permeation across Excised Rat Skin", C18 Biol. Pharm. Bull., Vol. 18, No. 4, pp.571-575 (1995) C19 Oxytrol Data Sheet P. Karande and S. Mitragotri, "High Throughput Screening of Transdermal Formulations," C20 Pharmaceutical Research, 2002, 19(5): 655660. **EXAMINER** DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.